Summit Therapeutics and GSK Launch Clinical Trial Collaboration to Test Ivonescimab with GSK’s B7‑H3 ADC

Summit Therapeutics Inc. (NASDAQ: SMMT) has announced a new clinical trial collaboration with GSK plc to evaluate the investigational bispecific antibody ivonescimab in combination with GSK’s novel B7‑H3‑targeted antibody‑drug conjugate risvutatug rezetecan (GSK’227) across multiple solid tumor types, including small cell lung cancer (SCLC). Ivonescimab, a PD‑1/VEGF bispecific antibody designed to both block immune checkpoints and inhibit angiogenesis, will be supplied by Summit for the planned study, while GSK will lead day‑to‑day clinical operations. Under the non‑exclusive collaboration, each company retains rights to its respective product. Risvutatug rezetecan is an investigational B7‑H3‑targeting ADC that couples a fully human anti‑B7‑H3 antibody with a cytotoxic payload. The combination study aims to assess safety and potential anti‑tumor activity in patients with advanced solid tumors, with patient dosing anticipated to begin in mid‑2026. #oncology #clinicaltrials #biotech #SummitTherapeutics #SlimScan #GrowthStocks #CANSLIM